Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260412 | 0.87 | L3MBTL1 (0.54) | ALDH1A1OGFRL1ALOX15KDM4EL3MBTL1 | |
| SCHEMBL1261235 | 0.86 | TUBB4A (0.43) | ALDH1A1MAPK1TUBB4ATUBBTUBA3C | |
| SCHEMBL5141799 | 0.84 | MEN1 (0.52) | ALDH1A1MAPK1PIK3CAOPRM1OPRK1 | |
| SCHEMBL12894488 | 0.83 | TUBB4A (0.42) | ALDH1A1MAPK1TUBB4ATUBBTUBA3C | |
| SCHEMBL3750336 | 0.73 | RPS6KB1 (0.42) | ALDH1A1OPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL1260664 | 0.73 | L3MBTL1 (0.47) | ALDH1A1OPRM1OPRK1OGFRL1OPRD1 | |
| SCHEMBL5513984 | 0.72 | SIRT2 (0.56) | OPRM1OPRK1OGFRL1OPRD1L3MBTL1 | |
| SCHEMBL5513980 | 0.72 | SIRT2 (0.56) | OPRM1OPRK1OGFRL1OPRD1L3MBTL1 | |
| SCHEMBL12051172 | 0.72 | RPS6KB1 (0.48) | ALDH1A1MAPK1OPRM1OPRK1OGFRL1 | |
| SCHEMBL885809 | 0.72 | OPRM1 (0.47) | ALDH1A1MAPK1OPRM1OPRK1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2335700-A1 | Hepatitis C virus polymerase inhibitors with a heterobicylic structure | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2011-06-22 | — | — | EP | disclosed |
| US-7893084-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-7803944-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7576079-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-08-18 | — | — | US | disclosed |
| US-20090087409-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-04-02 | — | — | US | disclosed |
| EP-1891950-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1891951-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-02-27 | — | — | EP | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-20060293306-A1 | Viral Polymerase Inhibitors | BEAULIEU PIERRE L | 2006-12-28 | — | — | US | disclosed |
| US-7141574-B2 | Series of fused heterocycle compounds having improved inhibitory activity against HCV polymerase; hepatitis treatment | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20060160798-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2006-07-20 | — | — | US | disclosed |
| EP-1414441-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-05-06 | — | — | EP | disclosed |
| EP-1414797-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-05-06 | — | — | EP | disclosed |
| US-20040024190-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-02-05 | — | — | US | disclosed |
| US-20030176433-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-09-18 | — | — | US | disclosed |
| WO-2003010141-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003010140-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087409-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, MED25 | ALDH1A1 3616/4885MAPK1 1244/4885TUBB4A 2843/4885 |
| US-20030176433-A1 | Viral polymerase inhibitors | NR4A1, RCOR1, RER1 | ALDH1A1 2167/4885MAPK1 737/4885TUBB4A 1980/4885 |
| US-20060293306-A1 | Viral Polymerase Inhibitors | NR2C2, NR4A1, POLR2A | ALDH1A1 3405/4885MAPK1 903/4885TUBB4A 1597/4885 |
| US-20060160798-A1 | Viral polymerase inhibitors | NR4A1, NR1I3, RER1 | ALDH1A1 3899/4885MAPK1 866/4885TUBB4A 3936/4885 |
| US-20040024190-A1 | Viral polymerase inhibitors | RCOR1, NR4A1, RER1 | ALDH1A1 2367/4885MAPK1 929/4885TUBB4A 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.